CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73601501" target="_blank" >RIV/61989592:15110/20:73601501 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00098892:_____/20:N0000042
Výsledek na webu
<a href="https://obd.upol.cz/id_publ/333181387" target="_blank" >https://obd.upol.cz/id_publ/333181387</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.14501" target="_blank" >10.21873/anticanres.14501</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality
Popis výsledku v původním jazyce
BACKGROUND/AIM: Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. MATERIALS AND METHODS: Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis. RESULTS: Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21WAF/CIP1) detected in the TP53-deleted U266 cell line after SAHA treatment indicates the P53-independent mode of transcriptional activation of CDKN1A gene. In contrast, CDKN1A gene expression was significantly increased by both SBHA and SAHA treatment of TP53-mutated RPMI8226 cells. CONCLUSION: SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells. Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Název v anglickém jazyce
CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality
Popis výsledku anglicky
BACKGROUND/AIM: Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. MATERIALS AND METHODS: Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic acid (SAHA) and suberoylanilide hydroxamic acid (SBHA), were analyzed in multiple myeloma cell lines RPMI8226 and U266 with differing TP53 status using gene-expression analysis. RESULTS: Enhanced expression of cyclin-dependent kinase inhibitor 1A (CDKN1A/p21WAF/CIP1) detected in the TP53-deleted U266 cell line after SAHA treatment indicates the P53-independent mode of transcriptional activation of CDKN1A gene. In contrast, CDKN1A gene expression was significantly increased by both SBHA and SAHA treatment of TP53-mutated RPMI8226 cells. CONCLUSION: SAHA appears to be a potentially effective pro-apoptotic and anticancer drug with universal application in the treatment of heterogeneous populations of multiple myeloma cells. Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30109 - Pathology
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ANTICANCER RESEARCH
ISSN
0250-7005
e-ISSN
—
Svazek periodika
40
Číslo periodika v rámci svazku
9
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
9
Strana od-do
4979-4987
Kód UT WoS článku
000568990100003
EID výsledku v databázi Scopus
2-s2.0-85090260979